- Home
- NERV vs MBRX Comparison
NERV vs MBRX Comparison
Compare NERV & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- MBRX
- Stock Information
- Founded
- NERV 2007
- MBRX 2015
- Country
- NERV United States
- MBRX United States
- Employees
- NERV N/A
- MBRX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- MBRX Health Care
- Exchange
- NERV Nasdaq
- MBRX Nasdaq
- Market Cap
- NERV 12.4M
- MBRX 14.7M
- IPO Year
- NERV 2014
- MBRX 2016
- Fundamental
- Price
- NERV $1.84
- MBRX $0.67
- Analyst Decision
- NERV Hold
- MBRX Strong Buy
- Analyst Count
- NERV 1
- MBRX 2
- Target Price
- NERV $5.00
- MBRX $6.00
- AVG Volume (30 Days)
- NERV 15.2K
- MBRX 1.0M
- Earning Date
- NERV 08-05-2025
- MBRX 05-13-2025
- Dividend Yield
- NERV N/A
- MBRX N/A
- EPS Growth
- NERV N/A
- MBRX N/A
- EPS
- NERV 0.83
- MBRX N/A
- Revenue
- NERV N/A
- MBRX N/A
- Revenue This Year
- NERV N/A
- MBRX N/A
- Revenue Next Year
- NERV N/A
- MBRX N/A
- P/E Ratio
- NERV $2.23
- MBRX N/A
- Revenue Growth
- NERV N/A
- MBRX N/A
- 52 Week Low
- NERV $1.15
- MBRX $0.40
- 52 Week High
- NERV $3.69
- MBRX $4.90
- Technical
- Relative Strength Index (RSI)
- NERV 65.83
- MBRX 29.72
- Support Level
- NERV $1.75
- MBRX $0.62
- Resistance Level
- NERV $1.90
- MBRX $0.93
- Average True Range (ATR)
- NERV 0.12
- MBRX 0.07
- MACD
- NERV 0.04
- MBRX -0.03
- Stochastic Oscillator
- NERV 90.00
- MBRX 14.06
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.